US approves Eli Lilly's GLP-1 pill Foundayo: A new front in expanding weight-loss medication market

The FDA approved Eli Lilly’s once-daily oral GLP-1 pill, Foundayo, for weight loss, challenging Novo Nordisk’s injectable dominance. Foundayo offers convenience, broadens market access, and may reshape obesity treatment, but carries safety warnings.